Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B.

JCI Insight. 2018 Sep 6;3(17). pii: 121497. doi: 10.1172/jci.insight.121497. [Epub ahead of print]

2.

Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70).

Shao H, Li X, Moses MA, Gilbert LA, Kalyanaraman C, Young ZT, Chernova M, Journey SN, Weissman JS, Hann B, Jacobson MP, Neckers L, Gestwicki JE.

J Med Chem. 2018 Jul 26;61(14):6163-6177. doi: 10.1021/acs.jmedchem.8b00583. Epub 2018 Jul 13.

PMID:
29953808
3.

Fate of thiamethoxam in mesocosms and response of the zooplankton community.

Lobson C, Luong K, Seburn D, White M, Hann B, Prosser RS, Wong CS, Hanson ML.

Sci Total Environ. 2018 Oct 1;637-638:1150-1157. doi: 10.1016/j.scitotenv.2018.05.087. Epub 2018 May 14.

PMID:
29801208
4.

Development of a stress response therapy targeting aggressive prostate cancer.

Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D.

Sci Transl Med. 2018 May 2;10(439). pii: eaar2036. doi: 10.1126/scitranslmed.aar2036.

PMID:
29720449
5.

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.

Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP.

Haematologica. 2018 Jul;103(7):1218-1228. doi: 10.3324/haematol.2017.174482. Epub 2018 Apr 5.

6.

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.

Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC.

Oncotarget. 2016 Oct 18;8(48):83432-83445. doi: 10.18632/oncotarget.12735. eCollection 2017 Oct 13.

7.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

8.

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.

Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ.

Mol Cancer Res. 2017 Sep;15(9):1221-1229. doi: 10.1158/1541-7786.MCR-17-0196. Epub 2017 Jun 7.

9.

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA.

Cancer Res. 2017 Aug 15;77(16):4498-4505. doi: 10.1158/0008-5472.CAN-16-1944. Epub 2017 May 18.

10.

A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models.

Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR.

J Med Chem. 2016 Dec 22;59(24):11161-11170. doi: 10.1021/acs.jmedchem.6b01470. Epub 2016 Dec 12.

11.

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B.

J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14.

12.

Understanding the experience of care managers and relationship with patient outcomes: the COMPASS initiative.

Coleman KJ, Hemmila T, Valenti MD, Smith N, Quarrell R, Ruona LK, Brandenfels E, Hann B, Hinnenkamp T, Parra MD, Monkman J, Vos S, Rossom RC.

Gen Hosp Psychiatry. 2017 Jan - Feb;44:86-90. doi: 10.1016/j.genhosppsych.2016.03.003. Epub 2016 Aug 22.

PMID:
27558105
13.

Measuring the intrarenal distribution of glomerular volumes from histological sections.

Hann BD, Baldelomar EJ, Charlton JR, Bennett KM.

Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1328-36. doi: 10.1152/ajprenal.00382.2015. Epub 2016 Mar 16.

14.

Use of Cationized Ferritin Nanoparticles to Measure Renal Glomerular Microstructure with MRI.

Bennett KM, Beeman SC, Baldelomar EJ, Zhang M, Wu T, Hann BD, Bertram JF, Charlton JR.

Methods Mol Biol. 2016;1397:67-79. doi: 10.1007/978-1-4939-3353-2_7.

PMID:
26676128
15.

Phenotyping by magnetic resonance imaging nondestructively measures glomerular number and volume distribution in mice with and without nephron reduction.

Baldelomar EJ, Charlton JR, Beeman SC, Hann BD, Cullen-McEwen L, Pearl VM, Bertram JF, Wu T, Zhang M, Bennett KM.

Kidney Int. 2016 Feb;89(2):498-505. Erratum in: Kidney Int. 2016 May;89(5):1166-7.

16.

Preventing Radial Artery Occlusion by Using Reverse Barbeau Assessment: Bringing Evidence-Based Practice to the Bedside.

Bonnett C, Becker N, Hann B, Haynes A, Tremmel J.

Crit Care Nurse. 2015 Aug;35(4):77-82. doi: 10.4037/ccn2015428. No abstract available.

17.

TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response.

Rozanov D, Cheltsov A, Sergienko E, Vasile S, Golubkov V, Aleshin AE, Levin T, Traer E, Hann B, Freimuth J, Alexeev N, Alekseyev MA, Budko SP, Bächinger HP, Spellman P.

PLoS One. 2015 Jun 15;10(6):e0129566. doi: 10.1371/journal.pone.0129566. eCollection 2015.

18.

Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer.

Li X, Colvin T, Rauch JN, Acosta-Alvear D, Kampmann M, Dunyak B, Hann B, Aftab BT, Murnane M, Cho M, Walter P, Weissman JS, Sherman MY, Gestwicki JE.

Mol Cancer Ther. 2015 Mar;14(3):642-8. doi: 10.1158/1535-7163.MCT-14-0650. Epub 2015 Jan 6.

19.

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.

Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM.

Cell Rep. 2014 Aug 21;8(4):1037-48. doi: 10.1016/j.celrep.2014.07.010. Epub 2014 Aug 7.

20.

Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.

Davies JM, Robinson AE, Cowdrey C, Mummaneni PV, Ducker GS, Shokat KM, Bollen A, Hann B, Phillips JJ.

J Neurosurg. 2014 Feb;120(2):331-6. doi: 10.3171/2013.10.JNS13598. Epub 2013 Nov 29.

21.

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.

Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM.

Mol Cancer Ther. 2013 Oct;12(10):2213-25. doi: 10.1158/1535-7163.MCT-13-0104. Epub 2013 Aug 5.

22.

Pharmacological brake-release of mRNA translation enhances cognitive memory.

Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, Renslo AR, Sonenberg N, Walter P.

Elife. 2013 May 28;2:e00498. doi: 10.7554/eLife.00498.

23.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.

24.

Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.

LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS.

Cancer Res. 2013 Apr 1;73(7):2070-81. doi: 10.1158/0008-5472.CAN-12-3526. Epub 2013 Feb 11.

25.

Imaging a functional tumorigenic biomarker in the transformed epithelium.

LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93-8. doi: 10.1073/pnas.1218694110. Epub 2012 Dec 17.

26.

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M.

Cancer Discov. 2012 Aug;2(8):685-93. Epub 2012 May 24.

27.

Principles and emerging applications of nanomagnetic materials in medicine.

Clavijo-Jordan V, Kodibagkar VD, Beeman SC, Hann BD, Bennett KM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Jul-Aug;4(4):345-65. doi: 10.1002/wnan.1169. Epub 2012 Apr 9. Review.

PMID:
22488879
28.

TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH.

Clin Cancer Res. 2011 Nov 1;17(21):6754-65. doi: 10.1158/1078-0432.CCR-11-0544. Epub 2011 Oct 25.

29.

A tumor-suppressing function in the epithelial adhesion protein Trask.

Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM.

Oncogene. 2012 Jan 26;31(4):419-31. doi: 10.1038/onc.2011.246. Epub 2011 Jun 27.

30.

Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.

Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM.

J Mol Med (Berl). 2011 Sep;89(9):877-89. doi: 10.1007/s00109-011-0774-y. Epub 2011 Jun 16.

PMID:
21678117
31.

Experimental models to study lymphatic and blood vascular metastasis.

Chen L, Hann B, Wu L.

J Surg Oncol. 2011 May 1;103(6):475-83. doi: 10.1002/jso.21794. Review.

32.

Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ.

Cancer Res. 2011 Mar 15;71(6):2339-49. doi: 10.1158/0008-5472.CAN-10-2941. Epub 2011 Jan 31.

33.

On the use of micron-sized iron oxide particles (MPIOS) to label resting monocytes in bone marrow.

Tang KS, Hann B, Shapiro EM.

Mol Imaging Biol. 2011 Oct;13(5):819-24. doi: 10.1007/s11307-010-0437-3.

34.

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM.

Sci Transl Med. 2010 Jan 27;2(16):16ra7. doi: 10.1126/scitranslmed.3000389.

35.

Tumor detection by imaging proteolytic activity.

Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS.

Cancer Res. 2010 Feb 15;70(4):1505-12. doi: 10.1158/0008-5472.CAN-09-1640. Epub 2010 Feb 9.

36.

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB.

J Control Release. 2010 Jan 4;141(1):13-21. doi: 10.1016/j.jconrel.2009.08.006. Epub 2009 Aug 15.

PMID:
19686789
37.

MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.

Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM.

J Magn Reson Imaging. 2009 May;29(5):1071-9. doi: 10.1002/jmri.21737.

38.

Non-competitive androgen receptor inhibition in vitro and in vivo.

Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B, Diamond MI.

Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7233-8. doi: 10.1073/pnas.0807282106. Epub 2009 Apr 10.

39.

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.

Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S.

Cell. 2009 Apr 3;137(1):87-98. doi: 10.1016/j.cell.2009.01.039.

40.

Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM.

Clin Cancer Res. 2009 Apr 1;15(7):2311-22. doi: 10.1158/1078-0432.CCR-08-2533. Epub 2009 Mar 24.

41.

Multiple, novel biologically active endophytic actinomycetes isolated from upper Amazonian rainforests.

Bascom-Slack CA, Ma C, Moore E, Babbs B, Fenn K, Greene JS, Hann BD, Keehner J, Kelley-Swift EG, Kembaiyan V, Lee SJ, Li P, Light DY, Lin EH, Schorn MA, Vekhter D, Boulanger LA, Hess WM, Vargas PN, Strobel GA, Strobel SA.

Microb Ecol. 2009 Aug;58(2):374-83. doi: 10.1007/s00248-009-9494-z. Epub 2009 Feb 28.

PMID:
19252940
42.

Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles.

Bouchard LS, Anwar MS, Liu GL, Hann B, Xie ZH, Gray JW, Wang X, Pines A, Chen FF.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4085-9. doi: 10.1073/pnas.0813019106. Epub 2009 Feb 26.

43.

Bioactive endophytes warrant intensified exploration and conservation.

Smith SA, Tank DC, Boulanger LA, Bascom-Slack CA, Eisenman K, Kingery D, Babbs B, Fenn K, Greene JS, Hann BD, Keehner J, Kelley-Swift EG, Kembaiyan V, Lee SJ, Li P, Light DY, Lin EH, Ma C, Moore E, Schorn MA, Vekhter D, Nunez PV, Strobel GA, Donoghue MJ, Strobel SA.

PLoS One. 2008 Aug 25;3(8):e3052. doi: 10.1371/journal.pone.0003052.

44.

Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW.

Nano Lett. 2008 Sep;8(9):2851-7. doi: 10.1021/nl801488u. Epub 2008 Aug 20.

PMID:
18712930
45.

Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM.

J Magn Reson Imaging. 2007 Dec;26(6):1618-25.

46.

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.

Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC.

Mol Pharmacol. 2007 Jun;71(6):1525-34. Epub 2007 Mar 28.

47.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

48.

Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.

Marx C, Berger C, Xu F, Amend C, Scott GK, Hann B, Park JW, Benz CC.

Assay Drug Dev Technol. 2006 Jun;4(3):273-84.

PMID:
16834533
50.

A randomized treatment study to compare the efficacy of repeated nerve blocks with cognitive therapy for control of chronic head and neck pain.

Gale G, Nussbaum D, Rothbart P, Hann B, Leung V, Kanetz G.

Pain Res Manag. 2002 Winter;7(4):185-9.

PMID:
12518175

Supplemental Content

Support Center